Clinical trial NCT05133297: The Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis
Official title: A Phase 2A, Randomized, Double-blind, Double-dummy, Tofacitinib-parallel-group Study to Evaluate the Safety and Efficacy of TLL-018 in Active Rheumatoid Arthritis Who Had an Inadequate Response or Intolerance to Methotrexate.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Rheumatoid Arthritis
Lead sponsor: Hangzhou Highlightll Pharmaceutical Co., Ltd
Sponsor class: INDUSTRY
First posted: 2021-11-24
Enrollment: 101
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a randomized, double-blind, double-dummy, tofacitinib-parallel-group, phase 2A study to assess the safety and efficacy of TLL-018 in active rheumatoid arthritis subject who had an inadequate response or intolerance to methotrexate.


Eligibility criteria: Inclusion Criteria:

1. Diagnosed with RA based on either the 1987-revised American College of Rheumatology (ACR) classification criteria or the 2010 ACR/European League against Rheumatism (EULAR) criteria and have an inadequate response or intolerance to methotrexate.
2. Subjects must have been receiving oral or parenteral methotrexate therapy ≥ 3 months and on a stable prescription of 7.5 to 25 mg/week for at least 4 weeks prior to Baseline Visit.
3. Have active RA as defined by the following minimum disease activity criteria:

   * ≥ 6 swollen joints (based on 66 joint counts) at Screening and Baseline Visits;
   * ≥ 6 tender joints (based on 68 joint counts) at Screening and Baseline Visits;
   * high-sensitivity C-reactive protein (hsCRP) \> upper limit of normal (ULN) OR positive for both rheumatoid factor and anti-cyclic citrullinated peptide (CCP) at Screening.
4. For subjects with inadequate response to methotrexate, subjects must have discontinued all oral disease-modifying anti-rheumatic drugs (DMARDs) prior to Baseline Visit as specified below or for at least five times the mean terminal elimination half-life of a drug, whichever is longer:

   * ≥4 weeks prior to Baseline Visit for minocycline, penicillamine, sulfasalazine, hydroxychloroquine, chloroquine, azathioprine, gold formulations, cyclophosphamide;
   * ≥12 weeks prior to Baseline Visit for leflunomide if no elimination procedure was followed, or adhere to a washout procedure (i.e., 11 days washout with colestyramine, or 30 days washout with activated charcoal).
5. The organ function level must meet the following requirements:

Bone marrow: Blood routine results showed hemoglobin ≥90g/L, platelet ≥100×109/L, neutrophil absolute count ≥1.5×109/L; Liver: serum bilirubin ≤1.5 times the upper limit of normal value, aspartate aminotransferase (AST) ≤1.5 times the upper limit of normal value, alanine aminotransferase (ALT) ≤1.5 times the upper limit of normal value; Serum creatinine \<1.5 times the upper limit of normal value; Urine protein ≤1+, if urine protein \>1+, urine protein should be collected for 24 hours, the total amount should be ≤1 g. Female subjects of childbearing potential must test negative for pregnancy.

Exclusion Criteria:

1. History of Felty syndrome (Rheumatoid arthritis - Splenomegaly syndrome).
2. A history of herpes zoster or disseminated herpes simplex.
3. Treatment with any JAK inhibitor (tofacitinib, baricitinib, ruxolitinib) within 2 weeks prior to study start.
4. Subjects have severe, progressive or uncontrollable symptoms of kidney, liver, blood, gastrointestinal, lung, cardiovascular, neurological or brain disease.
5. Current treatment or treatment within 4 weeks or 5 half-lives (whichever is longer) prior to the first dose of study medication with another investigational medication or current enrollment in another investigational drug protocol.
6. If the laboratory T-Spot test (or other TB diagnostic test) is positive, the investigator will determine the activity based on the history and clinical manifestations, and the patients diagnosed as active TB should be excluded.
7. Positive blood screen for human immunodeficiency virus (HIV), hepatitis B surface antigen (HBsAg), or hepatitis C antibody.
8. Pregnant or breastfeeding female.

Primary outcomes:
measure: Number of Participants American College of Rheumatology 50% (ACR50) Response at Week 12
timeFrame: Week 12
Secondary outcomes:
measure: Number of Participants American College of Rheumatology 20% (ACR20) Response
timeFrame: Week 4, 8, 12, 16, 20 and 24
measure: Number of Participants Achieving American College of Rheumatology 50% (ACR50) Response
timeFrame: Weeks 4, 8, 12, 16, 20 and 24
measure: Number of Participants Achieving American College of Rheumatology 70% (ACR70) Response
timeFrame: Weeks 4, 8, 12, 16, 20 and 24
measure: Change From Baseline in Disease Activity Score Based on 28-Joints Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP)
timeFrame: Weeks 4, 8, 12, 16, 20 and 24
measure: Change From Baseline in Clinical Disease Activity Index (CDAI)
timeFrame: Weeks 4, 8, 12, 16, 20 and 24
measure: Changes From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score
timeFrame: Weeks 4, 8, 12, 16, 20 and 24
measure: Percent Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score
timeFrame: Weeks 4, 8, 12, 16, 20 and 24
measure: Change From Baseline in Patient's Global Assessment of Arthritis
timeFrame: Weeks 4, 8, 12, 16, 20 and 24
measure: Change From Baseline in Physician's Global Assessment of Arthritis
timeFrame: Weeks 4, 8, 12, 16, 20 and 24
Other outcomes:
Locations:
city: Beijing
country: China
facility: Peking Union Medical College Hospital
state: Beijing
Study officials:
References: